Member Info for RayPointer

Wild
Am I right in saying that Lindy's targeting citrullination is a prime example of targeting a small part of a much larger molecule?
i.e the arginine converted to citrulline is attached to a much larger protein molecule such as vimentin.

Yes, I can imagine the scenario that the Chinese banks would stump up the required cash.
I could also imagine the Chinese government strongly supporting such a transaction.

It would certainly catapult one lucky Chinese company into the pharma premier league IMHO.

yes, China pharmas are growing quickly and are keen to become future giants in the field.

But, at their current MCAPs could they afford to buy Scancell outright?
Maybe, maybe not.

Whereas, the current giants could easily afford to buy Scancell.

(Good luck to you C7 in your latest battle.)

Yes, it is very interesting with the different approaches.

Now if we could create mini neutron stars....

https://www.symmetrymagazine.org/article/scientists-observe-first-verified-neutron-star-collision

Totally off piste but I thought this might interest a few.
One area of science that China does appear to have a lead is nuclear fusion.

https://www.sciencealert.com/china-s-artificial-sun-has-officially-become-hot-enough-for-nuclear-fusion

This is surely the world's hottest topic.

https://www.fiercebiotech.com/partnering/eli-lilly-puts-cancer-immunotherapies-spotlight-360m-plus-biontech-deal

Lilly's deal with BionTech dates back to 2015

1) Looks like BionTech's TCR research and techniques are superior to any of Lilly's
2) Possibly BionTech are struggling to make any major breakthroughs
3) Possibly Moditope targets will provide those major breakthroughs

It seems likely to me that Lilly are keeping a close eye on the Scancell/BionTech collaboration

Yeah, not going to the original timetable but, I agree, 2019 is looking good.

Sorry

"Awaiting approval of Ichor Trigrid Version 2 by FDA"

should read

"Awaiting approval of Ichor Trigrid Version 2 IND by FDA"

Matt

Grand Challenge
Jan 2019 Winners announced

SCIB1 combo trial
Awaiting approval of Ichor Trigrid Version 2 by FDA
Scancell are helping Ichor with this
Trail expected to start H1 2019 - Scancell cannot be more specific

Modi1 trial
Manufacturing difficulties but Scancell have said that these have probably now been resolved
Toxicology report
CTA application
Trial was expected to start H1 2019 but IMHO will now be H2 2019

SCIB2 combo trial
CRUK are under no obligation to report progress
Delivery now to be by nano vesicle
Trail was expected to start H2 2019

BionTech
Possiibility of Modi1 deal
Possibility of Modi2 deal
No definite timescale but Scancell have said that the collaboration is going well

3rd platform - Glycans
Scancell have said expect news in 2019

Hope this helps.

https://www.drugs.com/history/keytruda.html

Not bang up-to-date (there was even another approval announcement today).
But this history clearly illustrates what an important cancer drug Keytruda has become and is still becoming.

So if SCIB1 can significantly increase the effectiveness of Keytruda on its own, imagine the interest this will generate.

Those who can, do. Those who can't become regulators.

Very sad that so many Chinese know that drugs are available but they just cannot afford them.
However, some are showing great ingenuity by actually manufacturing the drugs themselves.

Chinese pharma companies are very small compared to the giants in the rest of the world.
However, look at the growth rates between 2016 and 2017.

http://www.pharmexec.com/chinese-pharmaceutical-industry-winners-and-losers-2017

https://en.wikipedia.org/wiki/List_of_largest_biotechnology_and_pharmaceutical_companies

https://en.wikipedia.org/wiki/Smoking_in_China

Nearly 60% of male Chinese doctors are smokers, which is the highest proportion in the world.

I cannot think of a more "honourable gentleman" than RG to do the presentation.
2:20pm-2:40pm Scancell Holdings plc in Ballroom 2

I was googling T Cell affinity and found this

T Cells - at Amazon
www.amazon.co.uk/T Cells
T Cells, Low Prices. Free UK Delivery on Eligible Orders

I like your post, but not enough to kiss you!

It does look as though a lot of the groundwork is done during the international stage.
1) Written opinion
2) International search
3) International publication
4) Supplementary international search (optional)
5) International preliminary examination (optional)

As regards the slides, it may have just been an oversight on the AGM presentation and this was corrected for the Proactive presentation.

For the collaboration:
Lindy may have reached the point with Modi2 where she pretty well knows what peptides are included. She is in close contact with BionTech and the obvious question to Biontech would then be "Do you want to extend testing using Modi2?".
Judging by Lindy's comments about the collaboration progress the likely answer would be "Yes Please".

So, possibly 1 agreement that can be modified each time a new vaccine is firmed up on.

And then perhaps a separate deal for each vaccine (bearing in mind that some targets will be common between vaccines e.g. Enolase)

There were crucial differences between slide 38 in the AGM presentation and slide 14 in the proactive presentation

AGM slide entitled
Moditope TCR approach

Proactive slide entitled
Moditope TCR research collaboriation
plus BionTech logo displayed

https://www.ccc.ac.at/fileadmin/ccc/Upload_Newsmeldungen/1_NL_2017/Christoph_Huber_Biographical_sketch_07.2016.pdf

Christoph Huber would be a worthy substitute if Ugur Sahin got injured.